AZBio delivered data on life-changing innovation and the economic impact of Arizona’s life sciences industry to Arizona’s Congressional Delegation last week in meetings with 10 of Arizona’s 11 Congressional offices.
Category Archives: Advocacy and Regulations
Understanding Gov. Ducey’s $1 billion university research infrastructure plan
Building on Success for a Better Arizona – Your Letter Can Make a Difference – Click Here to Learn More
Bill to Streamline CMS’s Process for Breakthrough Technologies Introduced in the US Senate
The Ensuring Patient Access to Critical Breakthrough Products Act, will help bridge a gap between FDA and CMS and improve patient access to breakthrough medical technologies for serious illnesses, S. 2998, to expedite CMS decision-making for innovative medical technologies.Continue reading
Arizona Governor Ducey Signs Bill Ensuring Patient Access to Interchangeable Biologic Medicines
Communication Important for Patients and PhysiciansContinue reading
Arizonans advocating for a more accurate test for Lyme Disease
Focus On Lyme executive director to speak at Capitol Hill science forum. Arizona-based group advocates for a definitive test for Lyme disease being developed by TGenContinue reading
AZBio Watch List for April 25 2016
Learn more about the bills AZBio is tracking at the Arizona Legislature
Continue reading
HB 2310- Getting Ready for Biosimilars in Arizona
The FDA approved the first biosimilar in the U.S. in March of 2015 with more expected to be approved in 2016. Now, on a state by state basis, the laws that govern how these new therapies can be dispensed are being updated. Arizona has the opportunity to do so in 2016 with HB 2310 sponsored by Dr. Regina Cobb, Vice Chairman of the House Health Committee.Continue reading
Congress Suspends The Medical Device Tax for Two Years
Medical device innovators got good news on December 18th as Congress passed a two-year moratorium on a tax the industry said was limiting its growth. Companies and industry backers in Arizona and around the country have worked for years to repeal the 2.3 percent tax on revenue from medical device sales. Continue reading
BIO – The Week That Was for Nov 13th
|
|
| BIO Actions & Activities |
